Pharma major Novartis received a setback from the Indian Patent Office after the patent on its blockbuster cardiac drug Vymada was revoked due to lack of novelty, the Times of India reported on ...
The Controller General of Patents, Designs and Trademarks (CGPDTM), the Indian Patent Office, has annulled the patent granted to Novartis for its cardiac drug Vymada, also sold internationally as ...
Indian Patent Office (IPO) has revoked Novartis AG’s patent on its blockbuster heart-failure drug Entresto, sold as Vymada in India, saying the Swiss drug company’s claims lacked novelty. Vymada is ...
The Swiss firm had launched its brand in India in February 2017 and in-licensed it to Cipla and Lupin (File) A blockbuster heart failure drug by Swiss pharma major Novartis is going off-patent in ...
NEW DELHI: The Indian Patent Office (IPO) has revoked the patent on Novartis' cardiac blockbuster drug Vymada on grounds of lack of novelty, potentially paving the way for affordable generics to enter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results